There are more than a thousand publicly traded healthcare companies on US exchanges alone. Globally, hundreds more are listed on the LSE, Euronext, and exchanges across Asia-Pacific. Together they represent trillions of dollars in market value, thousands of clinical programs, and some of the most consequential innovation happening anywhere in the economy.
A significant number of these companies are essentially invisible to Wall Street. No sell-side analyst has ever written a word about them.
This is the healthcare analyst coverage gap, and it is costing companies more than most of them realize.
The numbers are stark
Across all sectors, approximately 3,000 publicly traded companies have no analyst coverage whatsoever, and healthcare is disproportionately represented among them. The sector is enormous by listed-company count, yet analyst attention is concentrated at the top. The 20 largest biopharmaceutical companies alone account for roughly $3.7 trillion in market cap, while hundreds of others compete for a fraction of analyst bandwidth. According to FactSet, a staggering 1,564 publicly traded healthcare companies across 40+ global markets have zero analyst coverage (as of August 2026).
Supply makes the picture worse. Across the 12 largest investment banks, sell-side analyst headcount fell nearly 30%, from around 4,400 in 2012 to approximately 3,100 by 2020. That means fewer analysts covering a universe of listed companies that has only grown. In Europe, sell-side coverage dropped measurably after MiFID II mandated the unbundling of research payments in 2018. A total of 334 firms lost coverage entirely, and European brokerage analyst headcount fell by more than 11%. This means that the gap has widened.
The listing pipeline keeps filling. Evaluate data show that by the end of Q3 2026, 23 biopharma IPOs on Western exchanges raised $8bn through the first three quarters of 2026, against 13 raising $1.66bn in all of 2025.
Being uncovered carries a cost
Zero analyst coverage creates a drag on company value. Academic research from the University of Florida found that stocks with no analyst coverage experienced a near 5% permanent positive return when coverage was initiated. The revaluation lasts, because the market prices in the information the analyst provides.
The reverse is also the case. Companies that lost analyst coverage following MiFID II saw liquidity decline by more than 12%. Bid-ask spreads widened, trading costs rose, and the information environment deteriorated. The companies paid for it in the only currency that matters: their stock price.
It’s a straightforward relationship. Analysts create information flow – they model the business, speak to management, attend conferences, write initiation reports, issue price targets, and update their models every quarter. That flow attracts institutional investors, tightens spreads, and creates the right conditions for a fair valuation. Without it, even a well-run company with strong fundamentals can trade indefinitely at a discount to its true potential value.
In healthcare, where scientific progress, regulatory milestones, and clinical data are highly complex, the informational role of a knowledgeable analyst is particularly hard to replace.
The concentration problem
If you walk through the analyst coverage landscape in healthcare, a pattern appears quickly. The largest companies by market cap, such as Eli Lilly, AbbVie, and Johnson & Johnson, have coverage from 20, 25, even 30+ analysts. Every earnings call has a queue of questions and every guidance update is dissected within hours.
Meanwhile, a biotech with a promising oncology program, a $400 million market cap, and three years of solid clinical progress might only have two analysts covering it. Or one. Or indeed none.
Much of this can be explained by incentives. Analyst research is expensive to produce, and initiating on a net new company demands a significant upfront investment of time and resources. Institutional clients have large pools of capital and can only move meaningfully in names with sufficient liquidity, a bar that many small caps do not clear. The economics of sell-side research therefore push coverage toward where institutional money already sits, which is where additional analysis adds the least value.
The result is a self-reinforcing cycle:
- Companies without coverage lack the investor base to generate liquidity.
- Companies without liquidity do not attract institutional investors.
- Companies without institutional investors do not attract analysts.
- Companies without analysts do not get invited to the conferences institutional investors attend.
Then it repeats.
Why this matters beyond the individual company
The amount of capital in play is growing, which raises the stakes. Evaluate data show biopharma M&A deal value reached $176.69bn through Q3 2026, already above the 2025 full-year total of $144.31bn, while venture funding of $24.55bn sits just $1.1bn short of last year’s total.
The coverage gap affects the healthcare investment ecosystem as a whole. Effective capital allocation depends on investors being able to identify, evaluate, and compare opportunities across the full landscape of listed companies. When a large share of that landscape sits outside professional analysis, capital flows less efficiently to where it is needed, whether that is a first-in-class therapy, a medical device breakthrough, or a diagnostic technology that could transform patient outcomes.
The overlooked companies are often the smallest, the newest, or the most scientifically complex. In a sector where complexity is the norm and misallocation is measured in patient outcomes as much as portfolio returns, the absence of independent research is a structural problem worth taking seriously.
The gap can be closed
Companies gain coverage. Analysts expand their lists. Issuer-paid research providers, independent firms, emerging market specialists, and sector-focused boutiques are actively covering parts of the universe that bulge-bracket banks have left behind.
And there are returns. A 5% permanent uplift at initiation on a company valued at $400 million is $20 million in market cap created, without a clinical milestone, a regulatory approval, or any change in the business itself. All it takes is information flowing where it previously did not.
What does it take to get there? This series looks at what analysts need to initiate coverage, what companies can do to become more discoverable, and where the structural constraints are most open to change.
This is the first in our series on the healthcare coverage gap, exploring the healthcare analyst coverage gap, investor conference access, and capital allocation interact in publicly traded healthcare companies. The next piece looks at the problem from the analyst’s side: why initiating on new healthcare names is harder than it should be, and what it would take to change that.
